The UPB1 antibody targets the enzyme Uridine Phosphorylase 1 (UPase1), encoded by the *UPP1* gene in humans. UPase1 plays a critical role in pyrimidine metabolism by catalyzing the reversible phosphorylation of uridine to uracil and ribose-1-phosphate, influencing nucleotide salvage pathways and cellular proliferation. This enzyme is highly expressed in certain cancers, including colorectal and hepatocellular carcinomas, where it supports tumor growth by modulating nucleotide availability and potentially contributing to chemotherapy resistance. UPB1 antibodies are essential tools in biomedical research, enabling the detection and quantification of UPase1 expression through techniques like Western blotting, immunohistochemistry, and ELISA. They help elucidate UPase1's role in cancer metabolism, its interaction with therapeutic agents, and its potential as a diagnostic or prognostic biomarker. Additionally, these antibodies aid in studying UPase1's involvement in non-cancerous conditions, such as inflammatory diseases and metabolic disorders. Developed as monoclonal or polyclonal reagents, UPB1 antibodies are validated for specificity and sensitivity across diverse experimental models, supporting both basic research and drug development efforts aimed at targeting pyrimidine metabolism pathways.